Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
July 11, 2024
Via
Benzinga
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
3 No-Brainer Stocks to Buy in July
July 08, 2024
Investors shouldn't have to think too hard about these great stocks.
Via
The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
July 08, 2024
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
Via
InvestorPlace
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
July 04, 2024
Via
Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
July 02, 2024
Via
Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
June 25, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
June 24, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Buy in July 2024
July 05, 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
Via
InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
7 High Priced Stocks That Would Benefit From a Stock Split
July 04, 2024
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names.
Via
InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
July 03, 2024
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a...
Via
Benzinga
Exposures
Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
June 20, 2024
Via
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
June 11, 2024
Via
Benzinga
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
June 28, 2024
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision...
Via
Benzinga
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
June 28, 2024
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
June 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks That Could Make Your Grandchildren Rich
June 27, 2024
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
Via
InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
June 24, 2024
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy...
Via
Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
June 24, 2024
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via
Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
June 21, 2024
Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks.
Via
InvestorPlace
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Via
Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.